Sugi Predict
/ Targets
/ ERCC1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to ERCC1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer |
PHASE3 | COMPLETED |
| Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
PHASE2 | COMPLETED |
| S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer |
PHASE2 | COMPLETED |
| Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer |
PHASE2 | WITHDRAWN |
| Satraplatin and Prednisone to Treat Prostate Cancer |
PHASE2 | COMPLETED |
| PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy |
PHASE2 | COMPLETED |
| S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction |
PHASE2 | COMPLETED |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer |
PHASE2 | COMPLETED |
| Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer |
PHASE2 | UNKNOWN |
| Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
PHASE2 | COMPLETED |
| First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
PHASE2 | UNKNOWN |
| Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer |
PHASE2 | WITHDRAWN |
| Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) |
PHASE2 | COMPLETED |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer |
PHASE2 | COMPLETED |
| Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) |
PHASE2 | UNKNOWN |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer |
PHASE1 | COMPLETED |
| Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy. |
nan | UNKNOWN |
| DNA Repair Genes and Outcomes in Patients With Stage III NSCLC |
nan | UNKNOWN |
| Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel |
nan | COMPLETED |
| Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome |
nan | UNKNOWN |
| Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate |
nan | COMPLETED |
| Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews |
nan | COMPLETED |
| Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182 |
nan | UNKNOWN |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity |
nan | UNKNOWN |
| Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab |
nan | COMPLETED |
| Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a ERCC1 binder may also engage these)